The immunologic Warburg effect: Evidence and therapeutic opportunities in autoimmunity.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms and preclinical/early clinical concepts without primary human trial data or systematic synthesis.
PubMed 32105390 · doi:10.1002/wsbm.1486
What was done
This narrative review synthesized evidence on the metabolic shift toward aerobic glycolysis in pro-inflammatory innate and adaptive immune cells (the immunologic Warburg effect) and examined potential interventions, including pharmacological enzyme inhibitors and glucose-restricted diets (such as the ketogenic diet), to treat autoimmune diseases.
What was found
The abstract reports no quantitative data or specific numerical endpoints. It describes that blocking aerobic glycolysis impairs pro-inflammatory immune cell survival, differentiation, and effector functions while promoting regulatory and anti-inflammatory phenotypes. The authors state that while animal studies and limited human proof-of-concept studies support these metabolic strategies, clinical safety and efficacy remain to be established.
Why it matters
Targeting the immunologic Warburg effect may exploit selective metabolic vulnerabilities in pathogenic immune cells, providing an avenue to treat autoimmune disorders without broad tissue toxicity.
Limits
The abstract contains no primary quantitative data, clinical trial outcomes, or systematic literature search methods. Clinical evidence remains largely restricted to preclinical animal models and early proof-of-concept observations.
Cited by
- supports Human lymphocytes are glycolytic and make ATP through glycolysis despite not being cancerous.